Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.36) by 91.67 percent. This is a 7.81 percent decrease over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $29.21 million which beat the analyst consensus estimate of $27.79 million by 5.10 percent.